Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
Cirrhosis
•
Hepatology
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
Does the pattern on chest CT help determine which patients with RA-ILD will respond to immunosuppression?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
Would you consider long term avatrombopag use in patients with cirrhosis requiring higher platelet counts for medical therapy?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
